TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06735053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality group
Description: Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo virtual reality group
Description: The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
Study: NCT05997381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.
Description: An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: An arthroscopic rotator cuff repair is performed using standard surgical procedure.
Study: NCT06444217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy
Study: NCT05859750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (6mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (6mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (6mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (10mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (10mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 (10mg/kg) on day 1, IV, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Description: liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Description: oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
Study: NCT05552625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TADIOS
Description: TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
Study: NCT03412045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: hyperbaric oxygen therapy applied to patients in vaso-occlusive crisis
Study: NCT06525675

Intervention type: DRUG
Intervention: Fulvestrant Injectable Product
Description: 500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.

Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: 2.5 mg letrozole per day, administered orally (continuous treatment)

Intervention type: DRUG
Intervention: Palbociclib 125mg
Description: orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)

Intervention type: DRUG
Intervention: Palbociclib 125mg
Description: orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
Study: NCT05675579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)
Study: NCT04907747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication
Study: NCT05223114

Intervention type: OTHER
Intervention: Not applicable (N/A)
Description: Not applicable to this study

Intervention type: OTHER
Intervention: Not applicable (N/A)
Description: Not applicable to this study

Intervention type: OTHER
Intervention: Not applicable (N/A)
Description: Not applicable to this study

Intervention type: OTHER
Intervention: Not applicable (N/A)
Description: Not applicable to this study
Study: NCT06018818

Intervention type: DEVICE
Group type: OTHER
Intervention: Amvia/Solvia pacemaker family
Description: Implantation of a pacemaker or CRT-P devices
Study: NCT05195944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Treatment
Description: The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period
Study: NCT05084833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Electronic educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Electronic educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Electronic educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary care provider activation
Description: Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
Study: NCT05047783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib Mesylate
Description: 3CL-protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib Mesylate
Description: 3CL-protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib Mesylate
Description: 3CL-protease inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05905510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Erector spinae plane block (L-ESPB)
Description: The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block (FICB)
Description: The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia plane block
Description: Patients will receive spinal anesthesia alone
Study: NCT04495010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT05334004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Human Immunodeficiency Virus (HIV) antiviral, given via suppository
Study: NCT05747794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel will be given as standard of care (chemotherapy)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching eftilagimod alpha
Study: NCT02217826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DG3173
Study: NCT05929703

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HELP
Description: This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAM-HELP
Description: Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
Study: NCT05244707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean style diet
Description: The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
Study: NCT04486157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A012
Description: The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akynzeo 300Mg-0.5Mg Capsule
Description: The subjects will be administrated Akynzeo by Orally with water.
Study: NCT05037526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G System
Description: Continuous glucose monitoring system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring blood glucose
Description: Standard Care
Study: NCT05803408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free oats
Description: Early vs late introduction of gluten free oats

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gluten-free oats
Description: Early vs late introduction of gluten free oats
Study: NCT06348550

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberol® K
Description: Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05728515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104
Description: Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
Study: NCT05545605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oligomannate
Description: Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: the control group (receiving placebo capsule) for 24 weeks.
Study: NCT06296589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Guilt Reduction Therapy
Description: Behavioral therapy for trauma related guilt and shame

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Behavioral exposure therapy for PTSD
Study: NCT05770375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA 40mg
Description: MDMA 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA 80mg
Description: MDMA 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA 120mg
Description: MDMA 120mg
Study: NCT04352296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure
Description: Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood pressure
Description: Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
Study: NCT05922657

Intervention type: DEVICE
Intervention: Cerene
Description: Real world use of Cerene.
Study: NCT04390048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
Study: NCT05717478

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rhBMP-2-BBM
Description: Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss+Bio-Gide
Description: Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)